ZYDUSLIFE Zydus Lifesciences Ltd Investments/Divestments Announcement 2023 - Phase 1 Clinical Trials Zydus announces IND clearance of a novel Anti-PCSK9 candidate, aiming to treat Dyslipidemia with a once-in-6-month dosing regimen through Phase 1 clinical trials..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd